Spore.Bio raises €8M for real-time pathogen detection in FMCG factories

Spore.Bio has developed the world's first real-time pathogen detection device for factories.
Spore.Bio raises €8M for real-time pathogen detection in FMCG factories

Today deeptech startup Spore.Bio announced that it has raised €8 million in Pre-Seed funding led by LocalGlobe to solve the critical health and safety challenges threatening the global fast-moving consumer goods (FMCG) market. 

Spore.Bio has built the world's first device for detecting pathogens immediately, directly on the factory floor.

It uses advanced machine learning models to train its system to identify the concentration of bacteria in food, drink, pharmaceuticals and cosmetic products before alerting quality managers to the potential risks.

Previously, quality sampling would typically take between five and 20 days, with products having to be sent off-site to external labs, at great time and financial expense. 

With Spore.Bio, manufacturers get almost real-time insights with unprecedented levels of traceability and transparency. This not only reduces cross-contamination risks, and costs but allows manufacturers to address sources of contamination before they pose a public health risk.

The company was founded by in 2023 by CEO Amine Raji (a food and beverage manufacturing expert who has worked at more than 50 factories around the world for companies such as Nestlé), CTO Maxime Mistretta, (PhD and Postdoctorate from Pasteur Institute in Microbiology) and COO Mohamed Tazi (second-time founder who sold his previous company Gymlib to EGYM). 

Combined with a team of scientists and engineers from across microbiology, machine learning, optics, photonics and chemometrics, they built the first functional version of Spore. Bio's technology in less than eight months and already signed commercial contracts. 
The waitlist for the first prototypes is already oversubscribed, with plans to deploy hardware and software systems globally next year.

Besides LocalGlobe, the round also included participation from EmergingTech Ventures, No Label Ventures, Famille C (Clarins Family Office), Better Angle, Mehdi Ghissassi (Google DeepMind), Roxane Varza (Station F) and more.

According to Amine Raji, CEO and co-founder of Spore.Bio: 

"Our mission is to redefine microbiology and to bring 21st-century technology to an age-old problem. 
The risks around pathogens in FMCGs are only growing, causing needless suffering for families and detrimental effects on the reputations and finances of global companies. 

We're delighted to be working with such a respected group of investors who have the technical and strategic backgrounds that will help us scale and grow Spore.Bio into a globally significant business."

Julia Hawkins, general partner at LocalGlobe said: 

"Spore.Bio's innovation is where photonics and AI meet the same level of bacterial detection as traditional methods, in real-time. It's not just a technological advancement; it's a stride towards a safer, healthier society and a clear case of how AI can solve real, industrial problems.

Every one of us, directly or indirectly, interacts with products from these industries.

Making sure these products are free from harmful bacteria should therefore be a significant concern for us all. The expert team's solution gives industry, manufacturers and consumers the confidence that their products are as safe as possible."

The funding will be used to accelerate the development and deployment of Spore.Bio's AI-powered technology and grow its team.

Lead image: Spore.Bio. Photo: Uncredited.

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.